MedTrace Logo

Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer

NCT02199418 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 132

Last updated 2017-01-25

No results posted yet for this study

Summary

The investigators hypotheses that paclitaxel combined with cisplatin in a weekly-based regimen as neoadjuvant chemotherapy is effective and tolerable for locally advanced breast cancer.

Conditions

  • Tubular Breast Cancer
  • Mucinous Breast Cancer
  • Invasive Ductal Breast Cancer
  • Inflammatory Breast Cancer

Interventions

DRUG

Paclitaxel

DRUG

Cisplatin

Sponsors & Collaborators

  • RenJi Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2015-11-30
Completion
2016-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02199418 on ClinicalTrials.gov